These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38900156)

  • 21. Proteasome Inhibition Overcomes ALK-TKI Resistance in
    Tanimoto A; Matsumoto S; Takeuchi S; Arai S; Fukuda K; Nishiyama A; Yoh K; Ikeda T; Furuya N; Nishino K; Ohe Y; Goto K; Yano S
    Clin Cancer Res; 2021 Mar; 27(5):1410-1420. PubMed ID: 33310890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis.
    Singh S; Kumar M; Kumar S; Sen S; Upadhyay P; Bhattacharjee S; M N; Tomar VS; Roy S; Dutt A; Kundu TK
    J Biol Chem; 2019 Sep; 294(38):14081-14095. PubMed ID: 31366730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1.
    Hu B; Li X; Chen L; Liu Z
    Lung; 2020 Apr; 198(2):415-422. PubMed ID: 32034480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Expressions of CUL4A and TP53 in Colorectal Cancer Predict Poor Survival.
    Li C; Bu J; Liao Y; Zhang J; Han J; Zhang H; Xing H; Li Z; Wu H; Liang L; Wang M; Qin W; Yang T
    Cell Physiol Biochem; 2018; 51(6):2829-2842. PubMed ID: 30562757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
    Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
    Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
    Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
    BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Desmoglein 2 compensates for desmoglein 3 but does not control cell adhesion via regulation of p38 mitogen-activated protein kinase in keratinocytes.
    Hartlieb E; Rötzer V; Radeva M; Spindler V; Waschke J
    J Biol Chem; 2014 Jun; 289(24):17043-53. PubMed ID: 24782306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The desmosomal cadherin desmoglein-3 acts as a keratinocyte anti-stress protein via suppression of p53.
    Rehman A; Cai Y; Hünefeld C; Jedličková H; Huang Y; Teck Teh M; Sharif Ahmad U; Uttagomol J; Wang Y; Kang A; Warnes G; Harwood C; Bergamaschi D; Kenneth Parkinson E; Röcken M; Wan H
    Cell Death Dis; 2019 Oct; 10(10):750. PubMed ID: 31582719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
    Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
    Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
    Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
    BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P120-catenin is a novel desmoglein 3 interacting partner: identification of the p120-catenin association site of desmoglein 3.
    Kanno M; Isa Y; Aoyama Y; Yamamoto Y; Nagai M; Ozawa M; Kitajima Y
    Exp Cell Res; 2008 May; 314(8):1683-92. PubMed ID: 18343367
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-18a inhibits hypoxia-inducible factor 1α activity and lung metastasis in basal breast cancers.
    Krutilina R; Sun W; Sethuraman A; Brown M; Seagroves TN; Pfeffer LM; Ignatova T; Fan M
    Breast Cancer Res; 2014 Jul; 16(4):R78. PubMed ID: 25069832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.
    Wu C; Rao X; Lin W
    Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Desmoglein 3 acting as an upstream regulator of Rho GTPases, Rac-1/Cdc42 in the regulation of actin organisation and dynamics.
    Tsang SM; Brown L; Gadmor H; Gammon L; Fortune F; Wheeler A; Wan H
    Exp Cell Res; 2012 Nov; 318(18):2269-83. PubMed ID: 22796473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wild-type and mutant p53 differentially regulate NADPH oxidase 4 in TGF-β-mediated migration of human lung and breast epithelial cells.
    Boudreau HE; Casterline BW; Burke DJ; Leto TL
    Br J Cancer; 2014 May; 110(10):2569-82. PubMed ID: 24714748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
    Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
    Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
    Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
    EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression and prognostic significance of m6A-related genes in TP53-mutant non-small-cell lung cancer.
    Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Zhou F; Li Z; Ming L
    J Clin Lab Anal; 2022 Jan; 36(1):e24118. PubMed ID: 34812534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.